Filing Details

Accession Number:
0000899243-16-025946
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-29 16:49:47
Reporting Period:
2016-07-28
Filing Date:
2016-07-29
Accepted Time:
2016-07-29 16:49:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643736 Michele Trucksis C/O Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
Chief Medical Officer And Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-28 4,156 $15.77 4,156 No 4 M Direct
Common Stock Disposition 2016-07-28 4,156 $35.18 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2016-07-28 4,156 $0.00 4,156 $15.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
296,904 2025-03-24 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on February 26, 2016.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.10 to $35.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option vested as to 25% of the shares on January 15, 2016. The remainder of the shares will vest in 12 equal quarterly installments thereafter.